Core role of H19 LncRNA in gastric cancer: From tumor ecosystem reprogramming to precision therapy

IF 2.7 3区生物学 Q2 GENETICS & HEREDITY

Gene Pub Date : 2026-01-15 Epub Date: 2025-11-05 DOI:10.1016/j.gene.2025.149871

Binbin Zeng , Jianing Zhu , Yaping Wang , Chen Gu , Wenxu Zhu , Qingqing Xu , Yuxuan Wu , Juping Chen , Yang Ai , Tianyu Zhou , Ying Lin , Lixin Hua , Yayun Qian

{"title":"Core role of H19 LncRNA in gastric cancer: From tumor ecosystem reprogramming to precision therapy","authors":"Binbin Zeng , Jianing Zhu , Yaping Wang , Chen Gu , Wenxu Zhu , Qingqing Xu , Yuxuan Wu , Juping Chen , Yang Ai , Tianyu Zhou , Ying Lin , Lixin Hua , Yayun Qian","doi":"10.1016/j.gene.2025.149871","DOIUrl":null,"url":null,"abstract":"<div><div>Gastric cancer (GC) is the fifth most common malignancy and the fourth leading cause of cancer-related death worldwide. Owing to its insidious onset, most patients are diagnosed at advanced stages, marked by high recurrence, frequent metastasis, and multidrug resistance, resulting in poor outcomes. Optimizing therapeutic strategies therefore remains an urgent priority. Increasing evidence links GC initiation and progression to dysregulated expression of both coding and non-coding genes. Among them, long non-coding RNAs (lncRNAs) which recognized as pivotal regulators of gene expression have emerged as promising biomarkers and therapeutic targets. This review focuses on the lncRNA H19, highlighting its role as a central molecular hub in gastric tumor progression. H19 modulates the tumor microenvironment, promotes invasion and metastasis, reprograms cellular metabolism, and contributes to therapeutic resistance. By integrating molecular, cellular, and clinical perspectives, we provide a refined understanding of H19-driven gastric tumorigenesis and underscore its potential as a biomarker and therapeutic target. These insights offer new opportunities for early diagnosis, personalized treatment, and the development of RNA-targeted therapies for gastric cancer.</div></div>","PeriodicalId":12499,"journal":{"name":"Gene","volume":"976 ","pages":"Article 149871"},"PeriodicalIF":2.7000,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gene","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0378111925006602","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/11/5 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

Abstract

Gastric cancer (GC) is the fifth most common malignancy and the fourth leading cause of cancer-related death worldwide. Owing to its insidious onset, most patients are diagnosed at advanced stages, marked by high recurrence, frequent metastasis, and multidrug resistance, resulting in poor outcomes. Optimizing therapeutic strategies therefore remains an urgent priority. Increasing evidence links GC initiation and progression to dysregulated expression of both coding and non-coding genes. Among them, long non-coding RNAs (lncRNAs) which recognized as pivotal regulators of gene expression have emerged as promising biomarkers and therapeutic targets. This review focuses on the lncRNA H19, highlighting its role as a central molecular hub in gastric tumor progression. H19 modulates the tumor microenvironment, promotes invasion and metastasis, reprograms cellular metabolism, and contributes to therapeutic resistance. By integrating molecular, cellular, and clinical perspectives, we provide a refined understanding of H19-driven gastric tumorigenesis and underscore its potential as a biomarker and therapeutic target. These insights offer new opportunities for early diagnosis, personalized treatment, and the development of RNA-targeted therapies for gastric cancer.

查看原文本刊更多论文

H19 LncRNA在胃癌中的核心作用：从肿瘤生态系统重编程到精准治疗

胃癌（GC）是世界上第五大最常见的恶性肿瘤，也是第四大癌症相关死亡原因。由于其发病隐匿，大多数患者诊断为晚期，特点是高复发，频繁转移和多药耐药，导致预后差。因此，优化治疗策略仍然是当务之急。越来越多的证据表明GC的发生和发展与编码和非编码基因的表达失调有关。其中，长链非编码rna （lncRNAs）被认为是基因表达的关键调控因子，已成为有希望的生物标志物和治疗靶点。这篇综述的重点是lncRNA H19，强调其在胃肿瘤进展中的中心分子枢纽作用。H19调节肿瘤微环境，促进侵袭和转移，重编程细胞代谢，并有助于治疗耐药。通过整合分子、细胞和临床观点，我们提供了对h19驱动的胃肿瘤发生的精细理解，并强调了其作为生物标志物和治疗靶点的潜力。这些见解为胃癌的早期诊断、个性化治疗和rna靶向治疗的发展提供了新的机会。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gene 生物-遗传学

CiteScore

6.10

自引率

2.90%

发文量

718

审稿时长

42 days

期刊介绍： Gene publishes papers that focus on the regulation, expression, function and evolution of genes in all biological contexts, including all prokaryotic and eukaryotic organisms, as well as viruses.